BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22744426)

  • 21. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.
    Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH
    Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
    Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
    Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [TP53 gene polymorphisms and colorectal cancer risk in Chinese population].
    Jia HR; He XL; Zhu ZZ; Jin XX; Wang AZ; Huang HY; Zhu J; Yu GB; Zhu GS
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1448-51. PubMed ID: 17785079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population.
    Sameer AS; Shah ZA; Syeed N; Banday MZ; Bashir SM; Bhat BA; Siddiqi MA
    Genet Mol Res; 2010 Apr; 9(2):651-60. PubMed ID: 20449797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.
    Khan SA; Idrees K; Forslund A; Zeng Z; Rosenberg S; Pincas H; Barany F; Offit K; Laquaglia MP; Paty PB
    J Surg Oncol; 2008 Jun; 97(7):621-5. PubMed ID: 18381604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.
    Liu G; Cescon DW; Zhai R; Zhou W; Kulke MH; Ma C; Xu W; Su L; Asomaning K; Heist RS; Wain JC; Lynch TJ; Christiani DC
    Dis Esophagus; 2010 Jan; 23(1):36-9. PubMed ID: 19302219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions.
    Bhowmik A; Das S; Bhattacharjee A; Choudhury B; Naiding M; Deka S; Ghosh SK; Choudhury Y
    Asian Pac J Cancer Prev; 2015; 16(14):5767-72. PubMed ID: 26320449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.
    Xiao M; Zhang L; Zhu X; Huang J; Jiang H; Hu S; Liu Y
    BMC Cancer; 2010 Apr; 10():147. PubMed ID: 20398418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma.
    Ma J; Zhang J; Ning T; Chen Z; Xu C
    J Hum Genet; 2012 Apr; 57(4):261-4. PubMed ID: 22336889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
    Zhang JN; Yi SH; Zhang XH; Liu XY; Mao Q; Li SQ; Xiong WH; Qiu YM; Chen T; Ge JW
    Genet Mol Res; 2012 Oct; 11(4):3618-28. PubMed ID: 23096687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
    Wang ML; Xu YX; Qian J; Wang FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies.
    Tian X; Dai S; Sun J; Jiang S; Jiang Y
    Oncotarget; 2017 Jan; 8(1):1156-1165. PubMed ID: 27901479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.
    Xue L; Han X; Liu R; Wang Z; Li H; Chen Q; Zhang P; Wang Z; Chong T
    Oncotarget; 2016 May; 7(22):31825-31. PubMed ID: 26025918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms of TP53 Arg72Pro and Pro47Ser among Egyptian patients with colorectal carcinoma.
    Elsaid A; Zahran R; Elshazli R; El-Sayed A; Abou Samra M; El-Tarapely F; Abdel-Malak C
    Arch Physiol Biochem; 2019 Jul; 125(3):255-262. PubMed ID: 29560751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.
    Zhang F; Xu L; Wei Q; Song X; Sturgis EM; Li G
    Surgery; 2013 May; 153(5):711-7. PubMed ID: 23218882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
    Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
    Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [ASSOCIATION OF CERTAIN SINGLE NUCLEOTIDE POLYMORPHISM GENES OF APOPTOSIS SYSTEM WITH A RISK OF DEVELOPMENT OF COLORECTAL CANCER IN RUSSIAN POPULATION].
    Alyeva MK; Zverev SY; Feldblyum IV; Noskova EY; Kanina AO; Markovich NI
    Zh Mikrobiol Epidemiol Immunobiol; 2016 Sep; (5):72-80. PubMed ID: 30695351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
    Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
    DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
    Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
    PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.